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Background: To evaluate a combined rheumatoid arthritis magnetic resonance imaging score (RAMRIS) for hand
and foot (HaF-score) in rheumatoid arthritis (RA).
Methods: Magnetic resonance imaging (MRI, 0.2 Tesla) of the dominant hand and foot of 26 ACPA positive RA
patients before and 6 months after initiation of methotrexate was obtained. RAMRIS of the hand was
complemented by corresponding scoring of the foot (MTP I-V; HaF-score). Disease Activity Score 28 (DAS28) and a
tender and swollen joint count (JC) of the joints scored in MRI were recorded. Changes in these scores (Δ) were
assessed.
Results: ΔHaF-score correlated significantly with ΔDAS28 (r = 0.820, 95%-CI 0.633-0.916). Correlations to ΔDAS28
were best for changes in the synovitis subscore (0.648) and bone marrow edema (0.703). Correlations to ΔDAS28
were significantly better for of the ΔHaF-score than ΔRAMRIS (0.499, 0.139-0.743, p = 0.0368).
All patients with at least moderate response (EULAR criteria, n = 11) had continuing disease activity on MRI,
including five cases with new erosions, three of them at the feet. Improvements of the hand JC or foot JC were
seen in 16 and 15 cases, respectively. However, MRI of the hand or feet improved in only 10 and 9 cases,
respectively. No patient fulfilled SDAI remission criteria.
Conclusions: The HaF-score identifies patients with continuing disease activity despite clinical response that
would have been missed by consideration of the traditional RAMRIS or the DAS28 alone. Response as opposed to
remission may be an insufficient goal in RA as all patients showed continuing disease activity, especially at the feet.
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Rheumatoid Arthritis (RA) is a systemic inflammatory
disease causing bone destruction and functional impair-
ment predominantly of the small joints of hands and feet
[1]. In order to impede destruction, remission became
the utmost goal in the therapy of RA [2]. Beside effective
treatment options including disease modifying anti-
rheumatic drugs (DMARD) and biologicals, effective and
sensitive tools for therapy monitoring are needed to
reach this target. In daily practice as well as in research,
therapy monitoring and response assessment are pre-
dominantly assessed by using the disease activity score
28 (DAS28) and correspondent response criteria as pro-
posed by the American College of Rheumatology and
the European League Against Rheumatism. The DAS28
comprises joints of the upper limbs, hands and the knees
[3] but completely omits the feet. However, joint damage
progression occur in patients considered to be in remis-
sion based on the DAS28, [4] especially in joints which
are not covered by the DAS28. Consequently, there is
evidence that the DAS28 might underestimate disease
activity [5]. Nevertheless Smolen et al. demonstrated
that the simplified disease activity index (SDAI), which
is based on the same 28 joints used for calculation of the
DAS28, has the highest predictive value for the develop-
ment of new erosions [6].
In addition to clinical examination, imaging such as
ultrasound and magnetic resonance imaging (MRI) play
an important role in the management of RA patients.
Although these high resolution imaging modalities are
known to confer advantages as opposed to conventional
radiographs of the hands and forefeet, the latter still
state the gold standard for long-term evaluation of bone
destruction. MRI, for instance, can depict earliest inflam-
matory joint changes such as bone marrow edema
(BME), synovitis, or pre-erosion that are not visible on
radiographs. Moreover, patients in clinical remission
may display signs of disease activity in MRI and Power
Doppler augmented ultrasound. These findings have a
potential impact on therapeutic decisions, [7,8] because
such findings were shown to provides a high predictive
value for radiographic joint destruction and prognosis.
Due to these data, MRI has become integrated part in
the assessment of RA [9,10].
The RA- MRI- Scoring (RAMRIS) system, a standard-
ized semiquantitative assessment of inflammatory soft
tissue and destructive bone alteration, facilitated the use
of MRI in outcome studies in RA [11-13]. Since most
studies used the established RAMRIS method for the
clinically dominant hand, little is known about inflam-
matory and radiomorphological changes of forefeet MRI
regarding the relation to disease activity and response to
DMARD therapy. Signs of joint inflammation of the foot
on MRI were found to be as prevalent as in the hand[14]. They may even be present in the absence of inflam-
matory MRI findings of the clinically predominantly in-
volved hand [15] as well as in the state of remission
based on the DAS28 [16]. The latter study was the first to
deploy the established RAMRIS system to the feet and has
recently proofed to be highly reliable [17]. To our know-
ledge, there are no data available comparing the estab-
lished RAMRIS score with a combined hand and foot
score (HaF-score) for measurements of disease activity,
radiological alteration and therapy response in RA.
The purpose of this study was to evaluate and com-
pare the traditional RAMRIS of the hand with a new
combined HaF-score in terms of clinical and serological
correlation and sensitivity to change in RA patients be-
fore and after initiation of DMARD monotherapy of
methotrexate (MTX), and to analyse the advantages of
additional MR imaging of the foot.
Methods
Patients
Between November 2009 and July 2012, 26 consecutive
patients were prospectively enrolled (18 female, 8 male;
mean age 52.9, range ± 29.9 years, mean disease
duration 8 weeks (SD 4.66, range 1–18 weeks), mean
DAS28 3.5 (SD 0.78, mean CRP 0.9 mg/dl (SD 1.1))
All patients met 2010 American College of Rheumatol-
ogy/European League Against Rheumatism Rheumatoid
arthritis classification criteria [18] and were anticitrulli-
nated peptide antibodies (ACPA) positive. 25 of 26 pa-
tients were positive for rheumatoid factor (RF). The
general exclusion criteria for MRI imaging with gadolin-
ium based contrast agent, were applied. Because of the
dedicated open MRI system claustrophobia could be de-
nied. Steroids were allowed up to a dose of 7.5 mg pred-
nisolone at start and throughout the study. All patients
received methotrexate at a dose of 15 mg, which could
be taken orally or subcutaneously, conversions from oral
to subcutaneous application were allowed. The dose of
MTX was kept stable over 6 months. All patients were
naïve to DMARD treatment before inclusion into the
study and received MTX as part of standard care.
MRI of the dominant hand and foot was carried
out prior to the initiation of MTX therapy and after
6 months. Routine parameters assessed during each visit
included physical examination and routine laboratory
tests including erythrocyte sedimentation rate (ESR) and
C-reactive protein levels (CRP). This study was approved
by the local review board and informed consent was ob-
tained from all participating subjects.
Magnetic resonance imaging
MR images of hands and feet were performed achieve
most available comfort for patients in a low-field (0.2 T)
dedicated open MR system (Esoate, C-Scan, Esaote
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ankle coil was used for image acquisition. The clinically
dominant hand and foot (determined by an experienced
rheumatologist) were imaged in a single session chan-
ging dedicated coil and patient position in every patient.
MRI data was obtained on two consecutive time points
(T0: prior to DMARD therapy, T1: after 6 month). The
image protocol for the hand comprised the following se-
quences: Coronal Short tau inversion recovery (STIR)
sequence with a field of view (FoV) of 180* 180 mm,
matrix size 192* 152, slice thickness 3 mm (Time to
repetition (TR) 2420 ms, echo time (TE) 26 ms, Time
to inversion (TI) 85 ms), coronal 3 dimensional T1-
weighted gradient echo sequence with a FoV of 180*
180* 60 mm, matrix size 192* 192* 40, slice thickness
1 mm (TR 50 ms, TE 16 ms) prior to and after intraven-
ous injection of contrast material (0.2 ml/kg bodyweight
of Gd-DTPA (Dotarem©, Guerbet GmbH, Germany)).
The following protocol was used for imaging of the foot:
Coronal STIR- sequence with a FoV of 190* 190 mm,
Matrix size 192* 152, slice thickness 3 mm (TR
1700 ms, TE 22 ms, TI 80 ms), coronal 3 dimensional
T1- weighted gradient echo sequence with a FoV of 180*
180* 70 mm, matrix size 192* 192* 40, slice thickness
1 mm (TR 50 ms, TE 16 ms) prior to and after intraven-
ous injection of contrast material (0.2 ml/kg bodyweight
of Gd-DTPA (Dotarem©)). The 3 dimensional T1-
weighted gradient echo sequences of the hand and foot
were additionally reconstructed in sagittal and axial
planes. The overall image acquisition time was 39 mi-
nutes (18 minutes for the hand and 21 minutes for
the foot). The plasma half-life time of Dotarem© is about
90 min. Inter-reader reliability of MRI scoring was
assessed by independent scoring of images at T0 by two
different experienced radiologists (FM and CB) blinded
to patient identity. The smalles detectable difference
(SSD) according to Lassere is reported.
Imaging data analysis
MR images were read in consensus by two board-
certified radiologists with special expertise in musculo-
skeletal MRI and trained for RAMRIS scoring. Sites
including for scoring on the hand MRI were: metacarpo-
phalangeal joints II-V (MCP), carpal bones, distal radius,
distal ulna, radiocarpal and distal radio-ulnar joint. At
the foot the metatarsophalangeal (MTP) joints I-V were
assessed. For each joint site, synovitis, BME and erosions
were semiquantitatively graded as subscores according
to the RAMRIS criteria [11]. The RAMRIS score of the
hand was calculated. A combined hand and foot score
(HaF-score) was calculated as a sum score of the RAM-
RIS and the MTP joint score including the subscores for
synovitis, BME and erosions of each joint comparable to
the calculation of the RAMRIS of the hand. The changesin the HaF-score or RAMRIS between the T0 and T1
(Δ) were further analyzed.
Laboratory and clinical parameters
Laboratory and clinical parameters collected at baseline
and follow-up were: ESR, CRP (mg/dl), DAS28 (based
on CRP) and simplified disease activity index (SDAI). All
clinical examinations were performed by an experienced
rheumatologist. Changes of these parameters between
T0 and T1 (Δ) were further analyzed.
Ethic approval
The study was approved by the ethic committee of
the medical faculty of the Heinrich-Heine University
Duesseldorf (Study number 3226).
Statistical analysis
Baseline and follow-up characteristics are described as
proportions for categorical variables and as mean and
standard deviation (SD) for continuous variables. Re-
ported correlation coefficients are according to Spear-
man. Confidence intervals are two-sided 95% confidence
intervals. Results with p <5% are considered to be sig-
nificant. Confidence intervals for correlation coefficients
have been calculated using the Fisher transform. Test for
difference of two correlation coefficients has been ac-
complished as described previously [19]. Effect sizes are
reported as standardized response means (SRMs) and
are calculated according to Middle and van Sonderen
[20]. Statistical analyses have been performed using R
version 2.15.2 (R Development Core Team).
Results
The mean value of DAS28 decreased from T0 (prior to
MTX-therapy) to T1 (after 6 months) from 3.45 (min.
2.3; max. 4.9) to 2.9 (min. 1.8; max 4.6), the mean CRP
decreased from 0.91 mg/dl (min. 0.3; max. 5.1) to
0.59 mg/dl (min. 0.3; max. 3.0). The mean RAMRIS de-
creased from 21.81 (min 0; max 53) to 21.69 (min 0;
max 63) and the mean HaF-score from 33.58 (min 4;
max 84) to 31.08 (min 2; max. 73) after 6 months
(Table 1). ΔHaF-score showed the highest correlation
with ΔDAS28 (T1-T0) (0.820 confidence interval (CI)
0.633-0.916) followed by Δsum score foot (0.522, CI
0.168-0.756) and ΔRAMRIS of the hand (0.662, CI 0.69-
0.85) (Table 2, Figure 1). ΔHaF-score had a significantly
higher correlation to ΔDAS28 than ΔRAMRIS (p =
0.0368). Correlations of ΔHaF-score to ΔSDAI values
were overall slightly weaker (0.662 CI 0.369-0.835), with
ΔSDAI demonstrating the highest correlations to ΔHaF-
score amongst the parameters considered (Table 2). No
patients reached remission based on SDAI criteria [3].
The evaluation of changes of the considered parameters
(i.e. synovitis and BME) over time, employing the SRMs,
Table 1 Comparison of radiological, laboratory and
clinical scores at baseline and after 6 month
Score T0 (baseline) T1 (after 6 month)
Min. Mean Max. Min. Mean Max.
DAS28 2.3 3.45 4.90 1.8 2.90 4.60
SDAI 4.3 14.99 29.10 3.4 11.55 27.30
CRP 0.3 0.91 5.10 0.3 0.59 3.00
BSG 4.0 23.04 62.00 3.0 16.43 58.00
Sum score hand 0 7.59 22 0 6.385 25
Sum score wrist 0 14.27 42 0 15.31 59
Sum score foot 0 11.77 44 0 9.385 33
RAMRIS 0 21.81 53 0 21.69 63
HaF-score 4 33.58 84 2 31.08 73
Sewerin et al. BMC Musculoskeletal Disorders 2014, 15:104 Page 4 of 8
http://www.biomedcentral.com/1471-2474/15/104showed a high effect size for the decrease of the DAS28
(−0.8188). In contrast, the effect size for the decrease in
the HaF-score was trivial (−0.13). Similarly, based on the
EULAR response criteria, eleven patients reached clin-
ical improvement with good or moderate response. In
the MRI follow-up (T1), all patients showed signs of
continuing disease activity on MRI, including all good
and moderate responder. Five of these showed actually
new erosions (Table 3).
The analysis of the different subscores of the HaF-
score with ΔDAS28 revealed that changes in synovitis
(0.648 CI 0.347-0.827) and BME (0.703 CI 0.434-0.857)
were best correlated. In comparison to the combined
HaF-score, MRI scoring for the foot alone, showed
markedly lower correlations to ΔDAS28 (Δsynovitis
0.485 (CI 0.12-0.734) and ΔBME 0.514 (CI 0.159-0.752))
(Table 4).
Next, the performance of the HaF-score against clin-
ical examination was assessed. For this purpose, all joints
considered in the HaF-score were examined on both
sides and the number of swollen joints was added to the
number of tender joints to create a sum score for the
hand (hand joint count) and the foot (foot joint count).
The hand count demonstrated worsening in six, un-
changed values in four, and an improvement in sixteenTable 2 Spearman-correlation between ΔDAS28 and ΔSDAI to
Change in score
(ΔT1-T0)
Correlations between ΔDAS28 and





sum score hand 0.368 0.022–
sum score wrist 0.449 0.075–
sum score foot 0.522 0.168–
RAMRIS* 0.499 0.139–
HaF–score* 0.820 0.633–
*Significant differences between ΔRAMRIS und ΔHaF-score (p = 0.0368) in correlatiopatients. Despite improvement in the hand joint count
on clinical examination, there was no improvement of
the traditional RAMRIS in 6 of 16 patients. The foot
joint count demonstrated worsening in two, unchanged
values in nine, and an improvement in fifteen patients.
Comparable to the traditional RAMRIS, the foot sub-
score of the new HaF-score uncovered 6 out of 15 pa-
tients with unchanged values or deterioration in spite of
clinical improvement (i.e. foot joint count) (Table 5).
The pattern of inflammatory changes within the HaF-
score was assessed. Overall, foot joints were more se-
verely involved based on the MRI sum scores of syno-
vitis, erosions and BME compared to the hand. Therein,
MTP-2 was the single most affected joint. Furthermore,
scoring of the MTP-2 showed the highest mean differ-
ences between T0 and T1 (Table 6).
Finally, inter-reader reliability of MRI scoring at T0
was assessed to estimate the generalizability of HaF-
scoring. SSD were as follows: RAMRIS: 4.77, HaF score:
4.60, RAMRIS subscore hand: 2.23, RAMRIS subscore
wrist: 4.10, HaF subscore foot: 1.81. In 24 of 26 patients,
the HaF subscore for the foot differed by only 1 or less.
In addition we analysed the inter-rater agreement at T0
for the subscores Syn, Ero and BME for MCP-2 and
MTP-2 as the most frequently involved joints. SDD were
as follows for MCP-2: Ero subscore 0.91, Syn subscore
1.03. BME subscore 1.91; MTP-2: Ero subscore 0.87, Syn
subscore 1.29, BME scubscore 0.87.
Discussion
This study is the first to evaluate a combined hand and
foot MRI score (HaF-score) for monitoring RA patients
under DMARD therapy with methotrexate. A combined
assessment on hand and feet is already established for
years in the assessment of conventional radiographs
[21-23]. However, MRI offers the potential for visualiz-
ing synovitis and BME, which was repeatedly shown to
be predictive for radiologic progression [10]. Moreover,
to our knowledge, this is the first systematic report of
combined hand and foot MRI in one session in RA pa-
tients. Patients had to be summoned for examinationchanges in other changes scores
fidence
val
Correlations between ΔSDAI and











Figure 1 Scatterplot of differences: HaF-Score (left figure) and RAMRIS (right figure) vs. DAS28.
Table 4 Spearman-Correlation between ΔDAS28 and
synovitis-, erosion- and bone marrow edema-subscore
between T0 and T1
Score Spearman-correlation 95% confidence interval
Syn overall 0.648 0.347–0.827
Ero overall 0.125 −0.275–0.489
BME overall 0.703 0.434–0.857
Syn hand 0.487 0.123–0.736
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high patient satisfaction.
We found that the HaF-score correlated with clinical
and laboratory measures of disease activity such as
DAS28, SDAI and CRP. Analysing each component of
the HaF-score separately, we found that changes in the
HaF-score subscores for synovitis and BME, but not ero-
sions, correlated with changes of the DAS28 and SDAI
after therapy. This was also true if subscores for different
anatomic regions were assessed separately (i.e. synovitis
or BME for the hand, wrist and foot), albeit to a lesser
degree. In comparison to clinical examination of the
hand and the feet (hand and foot joint count), twelve pa-
tients with remarkable improvement in the joint counts
after six months were uncovered by worsening or un-
changed HaF-scores in MRI.
Numerous studies suggest that the DAS28 reflects
disease activity [5,24]. A potential limitation to deter-
mining disease activity by the DAS28 allone is highl-
ited by the finding of disease progression dispite
clinical improvement or remission [25,26]. Krabben
et al. have recently shown that subclinical inflamma-
tion - detected in hand and foot MRI - frequently
occurs in ACPA positive patients [27]. Moreover,
Wechalekar et al. demonstrated in a prospective
study in RA-patients after six months of DMARD
therapy DAS28 remisson rates of 30% (SDAI 28%),
wherein 43% still showed active synovitis in the fore-





Mean Range Mean Range Mean Range
Syn –2.545 –10–2 –2.545 –8–2 –3.455 –12–0
Ero 0.7273 –3–4 0.5455 –1–4 0.5455 –1–4
BME –0.8182 –5–2 0.5455 –3–5 –3.273 –14–1
Syn = Synovitis, Ero = Erosion, BME = bone marrow edema.identified eleven RA patients as being in good or
moderate response, based on the EULAR response
criteria, who nevertheless showed signs of disease ac-
tivity on MRI. Five of them had new erosions – and
importantly, three of these erosions were located at
the foot. Moreover there were seven patients with an
improvement in (traditional hand) RAMRIS at T1
having new erosions, two of them in the foot. This is
reflected by the effect size changes in the HaF-score,
which were trivial while changes in DAS28 showed
large effect sizes. Similarly, patients deemed to have
improved based on the SDAI, a potentially more ac-
curate clinical compound measure for the prediction
of erosions in RA, [6] were uncovered to have con-
tinuing disease activity or deterioration based on MRI
HaF-score. Importantly, in accordance with our find-
ing that all patients had residual disease activity based
on the HaF-score, no patient in the study reached re-
mission based on SDAI criteria (SDAI < 3.3), which isEro hand −0.296 −0.613–0.104
BME hand 0.238 −0.164–0.573
Syn wrist 0.349 −0.044–0.649
Ero wrist 0.286 −0.114–0.606
BME wrist 0.326 −0.071–0.633
Syn foot 0.485 0.12–0.734
Ero foot −0.282 −0.603–0.119
BME foot 0.514 0.159–0.752
Syn = Synovitis, Ero = Erosion, BME = bone marrow edema.
Table 5 Comparison between ΔRAMRIS of the hand (a) and the foot (b) and corresponding changes in total tender
joint (TJ) and swollen joint (SJ) count
Differences in hand TJ-SJ count (T1-T0)
Improved Equal Worse
Improved 10 1 0
ΔRAMRIS of the hand (T1-T0) Equal 2 2 3
Worse 4 1 3
Differences in hand TJ-SJ count (T1-T0)
Improved Equal Worse
Improved 9 2 0
ΔRAMRIS of the foot (T1-T0) Equal 2 6 0
Worse 4 1 2
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ure for radiological disease progression [3]. The same
was true for all patients who reached remission in
DAS28 while even all of them showed residual dis-
ease activity in the HaF-score. Hence, the current
study stresses the importance of reaching remission
rather than a moderate or good response only.
This study is limited by small patient number. Moreover,
it could be argued that a clinical compound measure in-
cluding the feet such as the DAS44 would have been more
suitable for comparison with the new HaF-score. However,
unlike the DAS44, the DAS28 is nowadays considered to
be the gold standard for determining disease activity in
RA, not only in studies, but also in clinical practice. Due
to national guidelines for the application of X-rays, which
allow routine conventional X-rays to be obtained only
once a year, a comparison between changes in MRI and
X-rays was not possible in the course of 6 months. Fur-
thermore, additional MR parameters such as scoring of
tenosynovitis might be of additional value, but were not
featured in our study.Table 6 Most frequently affected joints
Affected joint Number of patients with
Syn, Ero or BME at T0










MCP =metacarpophalangeal joints, MTP =metatarsophalangeal joints.Based on the present results, longitudinal studies with
a longer time period evaluating the potential of a com-
bined hand and foot MRI score (HaF-score) to predict
long-term radiological and functional outcomes are
clearly warranted.
There is theoretical concern that generalizability of the
HaF score may be hampered by difficulties in scoring
the foot. However, inter-reader realiability for the HaF-
score and especially the foot subscore was excellent in
the present study. Thus, the HaF may be regarded as a
reliable scoring system for the assessment of hand and
foot inflammation.Conclusion
The HaF-score identifies patients with continuing dis-
ease activity despite clinical response that would have
been missed by consideration of the traditional RAMRIS
or the DAS28 alone. Response as opposed to remission
may be an insufficient goal in RA as all patients showed
continuing disease activity, especially at the feet.ber of patients with Syn,
Ero or BME at T02
Overall sumscore T1 Overall difference
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